The Duke Cancer Institute Brain Mets program provides coordinated care for patients whose cancer has spread to the brain. Specialists across neurosurgery, medical oncology, and radiation oncology work together to personalize treatment and support quality of life.
This structured overview highlights key components of care, timelines, and roles involved in managing brain metastases at Duke. It is designed to help patients and families understand what to expect at each stage.
| Care Phase | Primary Goal | Key Team Members | Typical Timeline |
|---|---|---|---|
| Initial Evaluation | Confirm extent of disease and symptoms | Neurologist, Neurosurgeon, Medical Oncologist | 1–2 weeks |
| Staging & Imaging | Map lesions and systemic disease | Radiologist, Pathologist, Oncology Nurse | 1–3 weeks |
| Treatment Planning | Design personalized multimodal plan | Radiation Oncologist, Surgeon, Medical Oncologist | 1–2 weeks |
| Active Treatment | Control tumors and manage symptoms | Neurosurgery, Radiation Oncology, Medical Oncology | Days to weeks |
| Follow-up & Survivorship | Monitor response and support recovery | Oncology Nurse, Rehabilitation Specialists | Ongoing |
Multidisciplinary Care Approach for Brain Mets
At the Duke Cancer Institute Brain Mets pathway, a multidisciplinary team reviews each case to align treatment with tumor biology, location, and patient goals. This collaboration helps ensure that surgical, radiation, and systemic options are sequenced safely and effectively.
Advanced Radiation Techniques
Specialized radiation approaches such as stereotactic radiosurgery and fractionated regimens are tailored to brain metastases. These methods aim to maximize tumor control while protecting healthy brain tissue and preserving cognitive function.
Surgical Evaluation and Intervention
Neurosurgeons at Duke assess the suitability of resection based on tumor number, location, and patient fitness. When appropriate, surgery can relieve symptoms, reduce tumor burden, and enable more effective subsequent therapies.
Systemic Therapy and Clinical Trials
Medical oncologists coordinate systemic treatments, including targeted agents and immunotherapies, often within clinical trials specific to brain metastases. These options are selected based on mutation status, prior treatments, and overall health.
Key Takeaways for Patients with Brain Mets
- Multidisciplinary planning ensures treatment aligns with tumor features and personal goals.
- Advanced radiation techniques can control brain lesions while preserving cognitive function.
- Surgery may help selected patients by reducing burden and improving symptom control.
- Systemic therapies, including trials, are integrated when biologically and clinically appropriate.
- Structured follow-up supports early detection of changes and optimal quality of life.
FAQ
Reader questions
What criteria determine whether I am a candidate for surgery at Duke?
You may be a surgical candidate if you have limited metastases, controlled systemic disease, and lesions that are accessible with low neurological risk. Your team will review imaging and overall health to recommend the safest approach.
How does stereotactic radiosurgery work for brain metastases?
Stereotactic radiosurgery delivers precisely focused radiation doses to tumors in one or few sessions. It is often used for smaller lesions to minimize exposure to surrounding brain and reduce recovery time compared to conventional radiation.
Can targeted therapy or immunotherapy be used if my cancer has spread to the brain?
Yes, certain targeted therapies and immunotherapies can cross the blood-brain barrier and are used to treat brain metastases. Treatment choice depends on tumor genetics, prior therapies, and how well symptoms are controlled.
What follow-up care should I expect after completing treatment at Duke?
Follow-up includes regular imaging, symptom monitoring, and supportive care such as rehabilitation or cognitive therapy. The care team will schedule visits to track response and adjust plans as needed for long-term wellbeing.